Astria Therapeutics Inc
ATXS12.950USD
-0.030-0.23%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
730.83MMarket Cap
LossP/E TTM
More Details of Astria Therapeutics Inc Company
Astria Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for allergic and immunological diseases. Its lead product candidate is Navenibart, a potential monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema (HAE), a rare, autosomal dominant genetic disorder. Its second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in clinical development for the treatment of atopic dermatitis (AD), an immune disorder associated with loss of skin barrier function and itching. It owns five patent families directed to navenibart. The first patent family is directed to the composition of matter of navenibart and its use in treating various plasma kallikrein associated disorders, including HAE. In the second patent family, it is directed to methods of treating various plasma-kallikrein-associated disorders, including HAE.
Astria Therapeutics Inc Info
Ticker SymbolATXS
Company nameAstria Therapeutics Inc
IPO dateJun 25, 2015
CEOMilne (Jill C)
Number of employees78
Security typeOrdinary Share
Fiscal year-endJun 25
Address22 Boston Wharf Road
CityBOSTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02210
Phone16173491971
Websitehttps://astriatx.com/
Ticker SymbolATXS
IPO dateJun 25, 2015
CEOMilne (Jill C)
Company Executives of Astria Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Jonathan Violin, Ph.D.
Dr. Jonathan Violin, Ph.D.
Independent Director
Independent Director
263.32K
--
Mr. Noah Clauser
Mr. Noah Clauser
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Elizabeth Higgins
Ms. Elizabeth Higgins
Investor Relations
Investor Relations
--
--
Dr. Joanne T. Beck, Ph.D.
Dr. Joanne T. Beck, Ph.D.
Independent Director
Independent Director
--
--
Dr. Jill C. Milne, Ph.D.
Dr. Jill C. Milne, Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
--
--
Mr. Gregg A. Lapointe, CPA
Mr. Gregg A. Lapointe, CPA
Independent Director
Independent Director
--
--
Mr. Andrew Komjathy
Mr. Andrew Komjathy
Chief Commercial Officer
Chief Commercial Officer
--
--
Dr. Sunil Agarwal, M.D.
Dr. Sunil Agarwal, M.D.
Independent Director
Independent Director
--
--
Mr. Benjamin Scott Harshbarger
Mr. Benjamin Scott Harshbarger
Chief Legal Officer
Chief Legal Officer
--
--
Ms. Andrea Matthews
Ms. Andrea Matthews
Chief Business Officer
Chief Business Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Jonathan Violin, Ph.D.
Dr. Jonathan Violin, Ph.D.
Independent Director
Independent Director
263.32K
--
Mr. Noah Clauser
Mr. Noah Clauser
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Elizabeth Higgins
Ms. Elizabeth Higgins
Investor Relations
Investor Relations
--
--
Dr. Joanne T. Beck, Ph.D.
Dr. Joanne T. Beck, Ph.D.
Independent Director
Independent Director
--
--
Dr. Jill C. Milne, Ph.D.
Dr. Jill C. Milne, Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
--
--
Mr. Gregg A. Lapointe, CPA
Mr. Gregg A. Lapointe, CPA
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sat, Dec 13
Updated: Sat, Dec 13
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Perceptive Advisors LLC
11.36%
Vestal Point Capital, LP
8.68%
Magnetar Capital Partners LP
5.80%
Glazer Capital, LLC
5.53%
BlackRock Institutional Trust Company, N.A.
5.12%
Other
63.51%
Shareholders
Shareholders
Proportion
Perceptive Advisors LLC
11.36%
Vestal Point Capital, LP
8.68%
Magnetar Capital Partners LP
5.80%
Glazer Capital, LLC
5.53%
BlackRock Institutional Trust Company, N.A.
5.12%
Other
63.51%
Shareholder Types
Shareholders
Proportion
Investment Advisor
28.14%
Investment Advisor/Hedge Fund
23.84%
Hedge Fund
18.13%
Private Equity
11.36%
Venture Capital
7.90%
Research Firm
5.11%
Individual Investor
0.48%
Pension Fund
0.16%
Bank and Trust
0.08%
Other
4.80%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
269
50.80M
126.27%
-7.05M
2025Q3
271
57.86M
129.67%
-9.44K
2025Q2
269
57.86M
123.87%
-817.29K
2025Q1
275
58.74M
126.09%
-12.42M
2024Q4
265
58.96M
121.54%
+1.61M
2024Q3
242
56.87M
118.44%
+826.13K
2024Q2
223
55.98M
116.83%
-1.95M
2024Q1
205
57.91M
92.40%
+7.18M
2023Q4
176
36.94M
76.24%
+12.81M
2023Q3
167
23.70M
99.95%
-1.73M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Perceptive Advisors LLC
6.49M
11.49%
--
--
Jun 30, 2025
Vestal Point Capital, LP
4.52M
8.01%
+342.00K
+8.18%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
3.18M
5.64%
-222.43K
-6.53%
Jun 30, 2025
Fidelity Management & Research Company LLC
3.66M
6.48%
-1.15M
-23.93%
Jun 30, 2025
TCG Crossover Management, LLC
2.76M
4.89%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
2.52M
4.47%
-116.58K
-4.41%
Jun 30, 2025
VR Adviser, LLC
2.46M
4.35%
--
--
Jun 30, 2025
Fidelity Institutional Asset Management
2.80M
4.97%
+671.87K
+31.52%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Return Stacked Bonds & Merger Arbitrage ETF
5.16%
Virtus LifeSci Biotech Clinical Trials ETF
1.53%
AltShares Event-Driven ETF
0.63%
ALPS Medical Breakthroughs ETF
0.29%
ProShares Ultra Nasdaq Biotechnology
0.09%
iShares Micro-Cap ETF
0.09%
AltShares Merger Arbitrage ETF
0.09%
Invesco Nasdaq Biotechnology ETF
0.07%
iShares Biotechnology ETF
0.05%
Avantis US Small Cap Equity ETF
0.05%
View more
Return Stacked Bonds & Merger Arbitrage ETF
Proportion5.16%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion1.53%
AltShares Event-Driven ETF
Proportion0.63%
ALPS Medical Breakthroughs ETF
Proportion0.29%
ProShares Ultra Nasdaq Biotechnology
Proportion0.09%
iShares Micro-Cap ETF
Proportion0.09%
AltShares Merger Arbitrage ETF
Proportion0.09%
Invesco Nasdaq Biotechnology ETF
Proportion0.07%
iShares Biotechnology ETF
Proportion0.05%
Avantis US Small Cap Equity ETF
Proportion0.05%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Aug 19, 2021
Merger
6→1
Aug 19, 2021
Merger
6→1
Aug 19, 2021
Merger
6→1
Aug 19, 2021
Merger
6→1
Date
Type
Ratio
Aug 19, 2021
Merger
6→1
Aug 19, 2021
Merger
6→1
Aug 19, 2021
Merger
6→1
Aug 19, 2021
Merger
6→1
FAQs
Who are the top five shareholders of Astria Therapeutics Inc?
The top five shareholders of Astria Therapeutics Inc are:
Perceptive Advisors LLC holds 6.49M shares, accounting for 11.49% of the total shares.
Vestal Point Capital, LP holds 4.52M shares, accounting for 8.01% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 3.18M shares, accounting for 5.64% of the total shares.
Fidelity Management & Research Company LLC holds 3.66M shares, accounting for 6.48% of the total shares.
TCG Crossover Management, LLC holds 2.76M shares, accounting for 4.89% of the total shares.
Perceptive Advisors LLC holds 6.49M shares, accounting for 11.49% of the total shares.
Vestal Point Capital, LP holds 4.52M shares, accounting for 8.01% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 3.18M shares, accounting for 5.64% of the total shares.
Fidelity Management & Research Company LLC holds 3.66M shares, accounting for 6.48% of the total shares.
TCG Crossover Management, LLC holds 2.76M shares, accounting for 4.89% of the total shares.
What are the top three shareholder types of Astria Therapeutics Inc?
The top three shareholder types of Astria Therapeutics Inc are:
Perceptive Advisors LLC
Vestal Point Capital, LP
Magnetar Capital Partners LP
Perceptive Advisors LLC
Vestal Point Capital, LP
Magnetar Capital Partners LP
How many institutions hold shares of Astria Therapeutics Inc (ATXS)?
As of 2025Q4, 269 institutions hold shares of Astria Therapeutics Inc, with a combined market value of approximately 50.80M, accounting for 126.27% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -3.40%.
What is the biggest source of revenue for Astria Therapeutics Inc?
In --, the -- business generated the highest revenue for Astria Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
